Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA

Michael J. Levy, Barham K. Abu Dayyeh, Larissa L. Fujii, Lisa Allyn Boardman, Jonathan E. Clain, Prasad G Iyer, Elizabeth Rajan, Mark Topazian, Kenneth Ke Ning Wang, Maurits J. Wiersema, Ferga C. Gleeson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: There are virtually no data concerning the risk of adverse events (AEs) following lower gastrointestinal (LGI) endoscopic ultrasound (EUS). Our aim was to determine the incidence and factors associated with AEs following LGI EUS fine needle aspiration (FNA). Methods: We conducted a prospective cohort study at a tertiary referral center. Five hundred and sixty-three patients underwent LGI EUS FNA between 1 January 2004 and 1 January 2012. We analyzed the 502 patients who had complete follow-up. AE severity was graded (1-5) utilizing Common Terminology Criteria or Visual Analog Scale. AEs were assessed during the procedures, in clinical follow-up, during phone interviews conducted at 7-14 days, and final clinical and/or phone interviews at 2-4 months. Results: AEs developed in 103 (20.5%) patients and were classified as grade 1, 2, 3, or 4 in 34 (6.8%), 41 (8.2%), 23 (4.6%), and 5 (1.0%) patients, respectively. Bleeding and pain were the commonest AEs. No deaths occurred. On multivariate analysis, AEs were associated with prior pain (odds ratio (OR): 3.83, 95% confidence interval (CI): 2.35-6.25), FNA from a site other than a lymph node (LN) or gut wall (OR: 2.26, 95% CI: 1.10-4.70), and malignant FNA cytology (OR: 1.80, 95% CI: 1.10-2.97); serious (grade 3-4) AEs were associated with prior pain (OR: 15.21, 95% CI: 5.04-45.85) and FNA from a site other than a LN or gut wall (OR: 3.25, 95% CI: 1.15-9.20). Conclusions: LGI EUS FNA is associated with a high rate of serious grades 3-4 AEs. This may reflect the total number of associated interventions and the frequency of underlying pathology and symptoms.

Original languageEnglish (US)
Pages (from-to)676-685
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume109
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Lower Gastrointestinal Tract
Fine Needle Biopsy
Odds Ratio
Confidence Intervals
Pain
Lymph Nodes
Interviews
Visual Analog Scale
Terminology
Tertiary Care Centers
Cell Biology
Cohort Studies
Multivariate Analysis
Prospective Studies
Pathology
Hemorrhage
Incidence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA. / Levy, Michael J.; Abu Dayyeh, Barham K.; Fujii, Larissa L.; Boardman, Lisa Allyn; Clain, Jonathan E.; Iyer, Prasad G; Rajan, Elizabeth; Topazian, Mark; Wang, Kenneth Ke Ning; Wiersema, Maurits J.; Gleeson, Ferga C.

In: American Journal of Gastroenterology, Vol. 109, No. 5, 2014, p. 676-685.

Research output: Contribution to journalArticle

Levy, Michael J. ; Abu Dayyeh, Barham K. ; Fujii, Larissa L. ; Boardman, Lisa Allyn ; Clain, Jonathan E. ; Iyer, Prasad G ; Rajan, Elizabeth ; Topazian, Mark ; Wang, Kenneth Ke Ning ; Wiersema, Maurits J. ; Gleeson, Ferga C. / Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA. In: American Journal of Gastroenterology. 2014 ; Vol. 109, No. 5. pp. 676-685.
@article{c1d94b046e6d48dba4f62fac14405749,
title = "Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA",
abstract = "Objectives: There are virtually no data concerning the risk of adverse events (AEs) following lower gastrointestinal (LGI) endoscopic ultrasound (EUS). Our aim was to determine the incidence and factors associated with AEs following LGI EUS fine needle aspiration (FNA). Methods: We conducted a prospective cohort study at a tertiary referral center. Five hundred and sixty-three patients underwent LGI EUS FNA between 1 January 2004 and 1 January 2012. We analyzed the 502 patients who had complete follow-up. AE severity was graded (1-5) utilizing Common Terminology Criteria or Visual Analog Scale. AEs were assessed during the procedures, in clinical follow-up, during phone interviews conducted at 7-14 days, and final clinical and/or phone interviews at 2-4 months. Results: AEs developed in 103 (20.5{\%}) patients and were classified as grade 1, 2, 3, or 4 in 34 (6.8{\%}), 41 (8.2{\%}), 23 (4.6{\%}), and 5 (1.0{\%}) patients, respectively. Bleeding and pain were the commonest AEs. No deaths occurred. On multivariate analysis, AEs were associated with prior pain (odds ratio (OR): 3.83, 95{\%} confidence interval (CI): 2.35-6.25), FNA from a site other than a lymph node (LN) or gut wall (OR: 2.26, 95{\%} CI: 1.10-4.70), and malignant FNA cytology (OR: 1.80, 95{\%} CI: 1.10-2.97); serious (grade 3-4) AEs were associated with prior pain (OR: 15.21, 95{\%} CI: 5.04-45.85) and FNA from a site other than a LN or gut wall (OR: 3.25, 95{\%} CI: 1.15-9.20). Conclusions: LGI EUS FNA is associated with a high rate of serious grades 3-4 AEs. This may reflect the total number of associated interventions and the frequency of underlying pathology and symptoms.",
author = "Levy, {Michael J.} and {Abu Dayyeh}, {Barham K.} and Fujii, {Larissa L.} and Boardman, {Lisa Allyn} and Clain, {Jonathan E.} and Iyer, {Prasad G} and Elizabeth Rajan and Mark Topazian and Wang, {Kenneth Ke Ning} and Wiersema, {Maurits J.} and Gleeson, {Ferga C.}",
year = "2014",
doi = "10.1038/ajg.2013.479",
language = "English (US)",
volume = "109",
pages = "676--685",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Prospective evaluation of adverse events following lower gastrointestinal tract EUS FNA

AU - Levy, Michael J.

AU - Abu Dayyeh, Barham K.

AU - Fujii, Larissa L.

AU - Boardman, Lisa Allyn

AU - Clain, Jonathan E.

AU - Iyer, Prasad G

AU - Rajan, Elizabeth

AU - Topazian, Mark

AU - Wang, Kenneth Ke Ning

AU - Wiersema, Maurits J.

AU - Gleeson, Ferga C.

PY - 2014

Y1 - 2014

N2 - Objectives: There are virtually no data concerning the risk of adverse events (AEs) following lower gastrointestinal (LGI) endoscopic ultrasound (EUS). Our aim was to determine the incidence and factors associated with AEs following LGI EUS fine needle aspiration (FNA). Methods: We conducted a prospective cohort study at a tertiary referral center. Five hundred and sixty-three patients underwent LGI EUS FNA between 1 January 2004 and 1 January 2012. We analyzed the 502 patients who had complete follow-up. AE severity was graded (1-5) utilizing Common Terminology Criteria or Visual Analog Scale. AEs were assessed during the procedures, in clinical follow-up, during phone interviews conducted at 7-14 days, and final clinical and/or phone interviews at 2-4 months. Results: AEs developed in 103 (20.5%) patients and were classified as grade 1, 2, 3, or 4 in 34 (6.8%), 41 (8.2%), 23 (4.6%), and 5 (1.0%) patients, respectively. Bleeding and pain were the commonest AEs. No deaths occurred. On multivariate analysis, AEs were associated with prior pain (odds ratio (OR): 3.83, 95% confidence interval (CI): 2.35-6.25), FNA from a site other than a lymph node (LN) or gut wall (OR: 2.26, 95% CI: 1.10-4.70), and malignant FNA cytology (OR: 1.80, 95% CI: 1.10-2.97); serious (grade 3-4) AEs were associated with prior pain (OR: 15.21, 95% CI: 5.04-45.85) and FNA from a site other than a LN or gut wall (OR: 3.25, 95% CI: 1.15-9.20). Conclusions: LGI EUS FNA is associated with a high rate of serious grades 3-4 AEs. This may reflect the total number of associated interventions and the frequency of underlying pathology and symptoms.

AB - Objectives: There are virtually no data concerning the risk of adverse events (AEs) following lower gastrointestinal (LGI) endoscopic ultrasound (EUS). Our aim was to determine the incidence and factors associated with AEs following LGI EUS fine needle aspiration (FNA). Methods: We conducted a prospective cohort study at a tertiary referral center. Five hundred and sixty-three patients underwent LGI EUS FNA between 1 January 2004 and 1 January 2012. We analyzed the 502 patients who had complete follow-up. AE severity was graded (1-5) utilizing Common Terminology Criteria or Visual Analog Scale. AEs were assessed during the procedures, in clinical follow-up, during phone interviews conducted at 7-14 days, and final clinical and/or phone interviews at 2-4 months. Results: AEs developed in 103 (20.5%) patients and were classified as grade 1, 2, 3, or 4 in 34 (6.8%), 41 (8.2%), 23 (4.6%), and 5 (1.0%) patients, respectively. Bleeding and pain were the commonest AEs. No deaths occurred. On multivariate analysis, AEs were associated with prior pain (odds ratio (OR): 3.83, 95% confidence interval (CI): 2.35-6.25), FNA from a site other than a lymph node (LN) or gut wall (OR: 2.26, 95% CI: 1.10-4.70), and malignant FNA cytology (OR: 1.80, 95% CI: 1.10-2.97); serious (grade 3-4) AEs were associated with prior pain (OR: 15.21, 95% CI: 5.04-45.85) and FNA from a site other than a LN or gut wall (OR: 3.25, 95% CI: 1.15-9.20). Conclusions: LGI EUS FNA is associated with a high rate of serious grades 3-4 AEs. This may reflect the total number of associated interventions and the frequency of underlying pathology and symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84899914431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899914431&partnerID=8YFLogxK

U2 - 10.1038/ajg.2013.479

DO - 10.1038/ajg.2013.479

M3 - Article

VL - 109

SP - 676

EP - 685

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -